GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Grace Therapeutics, Inc. (“Grace Therapeutics” or the “Company”) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (“CRL”) for the Company’s New Drug Application for GTx-104 revealing that the CRL referenced certain items “related to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.” The price of the Company’s stock dropped following this news.
If you purchased Grace Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/grace-therapeutics/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
